Oxford BioDynamics’ Oxford Lab Achieves UKAS Accreditation for EpiSwitch® Tests

Oxford BioDynamics ( (GB:OBD) ) has shared an announcement.

Oxford BioDynamics has announced that its Oxford-based laboratory has been accredited by the United Kingdom Accreditation Service (UKAS) under the ISO 15189 standard, allowing it to conduct EpiSwitch® Clinical Tests in the UK. This accreditation marks a significant milestone for the company, as it enhances the turnaround time for test results and supports the company’s strategy to centralize its clinical testing operations in the UK. The successful validation of the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the UK lab is expected to benefit cancer patients by reducing the time taken to receive test results, thereby strengthening the company’s position in the diagnostics industry and its relationship with partners like Bupa UK.

Spark’s Take on GB:OBD Stock

According to Spark, TipRanks’ AI Analyst, GB:OBD is a Neutral.

Oxford BioDynamics exhibits significant financial and technical challenges, with persistent net losses, increasing leverage, and weak technical indicators. However, positive corporate events, such as insider buying and strategic partnerships, provide some optimism. The overall score reflects the need for substantial financial and operational improvements despite positive developments in corporate activities.

To see Spark’s full report on GB:OBD stock, click here.

More about Oxford BioDynamics

Oxford BioDynamics is a precision clinical diagnostics company that specializes in developing specific and sensitive tests for the medical field using its EpiSwitch® 3D genomics platform. The company focuses on providing diagnostic solutions that support healthcare providers and patients, particularly in the UK and Europe.

Average Trading Volume: 13,189,600

Technical Sentiment Signal: Sell

Current Market Cap: £7.83M

See more data about OBD stock on TipRanks’ Stock Analysis page.